Clinical trials: Advanced Liver Cancers
Neoplasms
Asian Phase I Study Of PF-03446962
This is an Asian Phase 1, multi center, open label, single arm study of PF 03446962 with dose escalation and designed to define the Maximum Tolerated Dose [MTD] and the Recommended Phase 2 Dose [RP2D].
- Trial name
- NCT01337050
- Testing
- PF-03446962
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 36 people
- Sponsor
- Pfizer
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic…
- Trial name
- FIDES-01 (NCT03230318)
- Testing
- derazantinib
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 148 people
- Sponsor
- Basilea Pharmaceutica
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01730937
- Testing
- Sorafenib, stereotactic body radiation therapy
- Where
- 51 sites in United States, Australia and 3 more
- Volunteers
- 193 people
- Sponsor
- Radiation Therapy Oncology Group
Hepatocellular Carcinoma, Liver Metastases
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
This is a phase 1b/2, multicenter, open-label, basket trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors alone and in combination with systemic intravenous (IV) administration of…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
- Trial name
- MASTERKEY-318 (NCT02509507)
- Testing
- Talimogene Laherparepvec, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 127 people
- Sponsor
- Amgen
Hepatocellular Carcinoma
Nivolumab Combined With BMS-986253 in HCC Patients
A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy…
- Trial name
- NCT04050462
- Testing
- Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- NYU Langone Health
Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of tivozanib and to see how well it works in treating patients with liver cancer that has spread to other parts of the body or cannot be removed by surgery.
- Trial name
- NCT01835223
- Testing
- Tivozanib (1mg), Tivozanib (1.5mg)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Roswell Park Cancer Institute
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00787787
- Testing
- sunitinib malate, capecitabine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unacceptable side effects, for combination treatment of nivolumab and yttrium Y 90…
- Conditions
- Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma
- Trial name
- NCT02837029
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or…
- Trial name
- NCT02519348
- Testing
- Tremelimumab, Durvalumab, Bevacizumab
- Where
- 44 sites in United States, China and 7 more
- Volunteers
- 433 people
- Sponsor
- MedImmune LLC
Advanced Hepatocellular Carcinoma
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related deaths globally and in Korea. Many patients diagnosed at advanced stage, and systemic therapy is mainstay of treatment in patients with advanced…
- Trial name
- NCT04862949
- Testing
- Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 131 people
- Sponsor
- CHA University
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Liver Cancer
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00483405)
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00101036
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma.
- Trial name
- NCT01754987
- Testing
- Ascorbic Acid + Sorafenib, Sorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
IMC-A12 in Treating Patients With Advanced Liver Cancer
This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00639509
- Testing
- cixutumumab, computed tomography, contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carinoma
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in…
- Trial name
- FLASH (NCT01636284)
- Testing
- JX-594 recombinant vaccina GM-CSF
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 16 people
- Sponsor
- Jennerex Biotherapeutics